Advertisement

Elevated plasma inflammatory mediators in post-polio syndrome: No association with long-term functional decline

      Highlights

      • A key feature of post-polio syndrome (PPS) is progressive loss of muscle strength.
      • In other chronic diseases muscle wasting has been linked to systemic inflammation.
      • PPS-patients had significantly increased levels of plasma TNF-α, IL-6, IL-8, and leptin compared to healthy controls.
      • Raised systemic levels of inflammatory mediators were not associated with a faster rate of clinical decline.

      Abstract

      A key feature of post-polio syndrome (PPS) is progressive loss of muscle strength. In other chronic diseases systemic inflammation has been linked to muscle wasting. In this study plasma TNF-α, IL-6, IL-8, and leptin levels were significantly increased in PPS-patients compared to healthy controls. There was however no association between these raised systemic levels of inflammatory mediators and long-term decline in quadriceps strength or other clinical parameters. In conclusion, there is evidence for systemic inflammation in PPS, yet the relationship with clinical deterioration remains tenuous.

      Abbreviations:

      PPS (post-polio syndrome), MU-size (motor unit size), MUAPs (single motor unit action potentials), mRNA (messenger RNA), CNS (central nervous system)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baeten D.
        • Baraliakos X.
        • Braun J.
        • Sieper J.
        • Emery P.
        • van der Heijde D.
        • Mcinnes I.
        • van Laar J.M.
        • Landewe R.
        • Wordsworth P.
        • Wollenhaupt J.
        • Kellner H.
        • Paramarta J.
        • Wei J.
        • Brachat A.
        • Bek S.
        • Laurent D.
        • Li Y.
        • Wang Y.A.
        • Bertolino A.P.
        • Gsteiger S.
        • Wright A.M.
        • Hueber W.
        Anti-interleukin-17a monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2013; 382: 1705-1713
        • Barnes M.A.
        • Carson M.J.
        • Nair M.G.
        Non-traditional cytokines: how catecholamines and adipokines influence macrophages in immunity, metabolism and the central nervous system.
        Cytokine. 2015; 72: 210-219
        • Bickerstaffe A.
        • van Dijk J.P.
        • Beelen A.
        • Zwarts M.J.
        • Nollet F.
        Loss of motor unit size and quadriceps strength over 10 years in post-polio syndrome.
        Clin. Neurophysiol. 2014; 125: 1255-1260
        • Bickerstaffe A.
        • Beelen A.
        • Nollet F.
        Change in physical mobility over 10 years in postpoliosyndrome.
        Neuromuscul. Disord. 2015; 25: 225-230
        • Chowdhury S.
        • Dijkhuis A.
        • Steiert S.
        • Lutter R.
        Il-17 attenuates degradation of are-mrnas by changing the cooperation between AU-binding proteins and microRNA16.
        PLoS Genet. 2013; 9e1003747
        • Dalakas M.C.
        New neuromuscular symptoms after old polio (“the post-polio syndrome”): clinical studies and pathogenetic mechanisms.
        Birth Defects Orig. Artic. Ser. 1987; 23: 241-264
        • Dalakas M.C.
        Morphologic changes in the muscles of patients with postpoliomyelitis neuromuscular symptoms.
        Neurology. 1988; 38: 99-104
        • Dalakas M.C.
        Pro-inflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome?.
        J. Neurol. Sci. 2002; 205: 5-8
        • Dalakas M.C.
        • Elder G.
        • Hallett M.
        • Ravits J.
        • Baker M.
        • Papadopoulos N.
        • Albrecht P.
        • Sever J.
        A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms.
        N. Engl. J. Med. 1986; 314: 959-963
        • Drost G.
        • Stegeman D.F.
        • Schillings M.l.
        • Horemans H.l.
        • Janssen H.M.
        • Massa M.
        • Nollet F.
        • Zwarts M.J.
        Motor unit characteristics in healthy subjects and those with postpoliomyelitis syndrome: a high-density surface EMG study.
        Muscle Nerve. 2004; 30: 269-276
        • Farbu E.
        • Rekand T.
        • Vik-Mo E.
        • Lygren H.
        • Gilhus N.E.
        • Aarli J.A.
        Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study.
        Eur. J. Neurol. 2007; 14: 60-65
        • Fordyce C.B.
        • Gagne D.
        • Jalili F.
        • Alatab S.
        • Arnold D.l.
        • Da C.D.
        • Sawoszczuk S.
        • Bodner C.
        • Shapiro S.
        • Collet J.P.
        • Robinson A.
        • Le Cruguel J.P.
        • Lapierre Y.
        • Bar-or A.
        • Trojan D.A.
        Elevated serum inflammatory markers in post-poliomyelitis syndrome.
        J. Neurol. Sci. 2008; 271: 80-86
        • Frisullo G.
        • Angelucci F.
        • Mirabella M.
        • Caggiula M.
        • Patanella K.
        • Nociti V.
        • Tonali P.A.
        • Batocchi A.P.
        Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients.
        J. Clin. Immunol. 2004; 24: 287-293
        • Ginsberg A.H.
        • Gale Jr., M.J.
        • Rose L.M.
        • Clark E.A.
        T-cell alterations in late postpoliomyelitis.
        Arch. Neurol. 1989; 46: 497-501
        • Gligorijevic I.
        • Van Dijk J.P.
        • Mijovic B.
        • Van H.S.
        • Blok J.H.
        • De V.M.
        A new and fast approach towards semg decomposition.
        Med. Biol. Eng. Comput. 2013; 51: 593-605
        • Gonzalez H.
        • Khademi M.
        • Andersson M.
        • Wallstrom E.
        • Borg K.
        • Olsson T.
        Prior poliomyelitis-evidence of cytokine production in the central nervous system.
        J. Neurol. Sci. 2002; 205: 9-13
        • Gonzalez H.
        • Khademi M.
        • Andersson M.
        • Piehl F.
        • Wallstrom E.
        • Borg K.
        • Olsson T.
        Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production.
        J. Neuroimmunol. 2004; 150: 139-144
        • Gonzalez H.
        • Ottervald J.
        • Nilsson K.C.
        • Sjogren N.
        • Miliotis T.
        • Von Bahr H.
        • Khademi M.
        • Eriksson B.
        • Kjellstrom S.
        • Vegvari A.
        • Harris R.
        • Marko-Varga G.
        • Borg K.
        • Nilsson J.
        • Laurell T.
        • Olsson T.
        • Franzen B.
        Identification of novel candidate protein biomarkers for the post-polio syndrome — implications for diagnosis, neurodegeneration and neuroinflammation.
        J. Proteome. 2009; 71: 670-681
        • Gonzalez H.
        • Khademi M.
        • Borg K.
        • Olsson T.
        Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up.
        J. Neuroinflammation. 2012; 9: 167
        • Halstead L.S.
        • Rossi C.D.
        New problems in old polio patients: results of a survey of 539 polio survivors.
        Orthopedics. 1985; 8: 845-850
        • Horemans H.L.
        • Nollet F.
        • Beelen A.
        • Drost G.
        • Stegeman D.F.
        • Zwarts M.J.
        • Bussmann J.B.
        • De V.M.
        • Lankhorst G.J.
        Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement.
        J. Neurol. Neurosurg. Psychiatry. 2003; 74: 1655-1661
        • Koopman F.S.
        • Beelen A.
        • Gilhus N.E.
        • De Visser M.
        • Nollet F.
        Treatment for postpolio syndrome.
        Cochrane Database Syst. Rev. 2015; 5cd007818
        • Lindemann R.A.
        The regulatory effects of monocytes on human natural killer cells activated by lipopolysaccharides.
        J. Periodontal Res. 1991; 26: 486-490
        • March of Dimes F.
        Post-polio syndrome: identifying best practices in diagnosis & care.
        in: White Plains. Identifying Best Practices in Diagnosis & Care. 2000
        • Mccomas A.J.
        • Quartly C.
        • Griggs R.C.
        Early and late losses of motor units after poliomyelitis.
        Brain. 1997; 120: 1415-1421
        • Melin E.
        • Lindroos E.
        • Lundberg I.E.
        • Borg K.
        • Korotkova M.
        Elevated expression of prostaglandin E2 synthetic pathway in skeletal muscle of prior polio patients.
        J. Rehabil. Med. 2014; 46: 67-72
        • Miller D.C.
        Post-polio syndrome spinal cord pathology. Case report with immunopathology.
        Ann. N. Y. Acad. Sci. 1995; 753: 186-193
        • Nollet F.
        • Beelen A.
        • Prins M.H.
        • De Visser M.
        • Sargeant A.J.
        • Lankhorst G.J.
        • De Jong B.A.
        Disability and functional assessment in former polio patients with and without postpolio syndrome.
        Arch. Phys. Med. Rehabil. 1999; 80: 136-143
        • Pezeshkpour G.H.
        • Dalakas M.C.
        Long-term changes in the spinal cords of patients with old poliomyelitis. Signs of continuous disease activity.
        Arch. Neurol. 1988; 45: 505-508
        • Phillips T.
        • Leeuwenburgh C.
        Muscle fiber specific apoptosis and tnf-alpha signaling in sarcopenia are attenuated by life-long calorie restriction.
        Fasten. J. 2005; 19: 668-670
        • Raqib R.
        • Ljungdahl A.
        • Lindberg A.A.
        • Wretlind B.
        • Andersson U.
        • Andersson J.
        Dissociation between cytokine mrna expression and protein production in shigellosis.
        Eur. J. Immunol. 1996; 26: 1130-1138
        • Sakuma K.
        • Aoi W.
        • Yamaguchi A.
        Current understanding of sarcopenia: possible candidates modulating muscle mass.
        Pflugers Arch. 2015; 467: 213-229
        • Schaap L.A.
        • Pluijm S.M.
        • Deeg D.J.
        • Harris T.B.
        • Kritchevsky S.B.
        • Newman A.B.
        • Colbert L.H.
        • Pahor M.
        • Rubin S.M.
        • Tylavsky F.A.
        • Visser M.
        • Health A.B.C.S.
        Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength.
        J. Gerontol. A Biol. Sci. Med. Sci. 2009; 64: 1183-1189
        • Sharief M.K.
        • Hentges R.
        • Ciardi M.
        Intrathecal immune response in patients with the post-polio syndrome.
        N. Engl. J. Med. 1991; 325: 749-755
        • Spate U.
        • Schulze P.C.
        Proinflammatory cytokines and skeletal muscle.
        Curr. Opin. Clin. Nutr. Metab. Care. 2004; 7: 265-269
        • Stolwijk-Swuste J.M.
        • Beelen A.
        • Lankhorst G.J.
        • Nollet F.
        SF36 physical functioning scale and 2-minute walk test advocated as core qualifiers to evaluate physical functioning in patients with late-onset sequelae of poliomyelitis.
        J. Rehabil. Med. 2008; 40: 387-394
        • Werhagen L.
        • Borg K.
        Effect of intravenous immunoglobulin on pain in patients with post-polio syndrome.
        J. Rehabil. Med. 2011; 43: 1038-1040